NORTH BILLERICA, Mass.--(BUSINESS WIRE)--May 7, 2019--
Lantheus
Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus
Medical Imaging, Inc. (“LMI”), a global leader in the development,
manufacture and commercialization of innovative diagnostic imaging
agents and products, today announced that Mary Anne Heino, President and
Chief Executive Officer, and Robert Marshall, Chief Financial Officer,
will present at the 2019 UBS Global Healthcare Conference at 1:00 p.m.
ET on Tuesday, May 21 at the Grand Hyatt New York.
To access a live webcast of the presentation, please visit the Investors
section of the Company’s website at www.lantheus.com.
A replay of the webcast will be available on the Company’s website for
30 days following the live presentation.
About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.
Lantheus
Holdings, Inc. is the parent company of LMI, a global leader in the
development, manufacture and commercialization of innovative diagnostic
imaging agents and products. LMI provides a broad portfolio of products,
including the echocardiography contrast agent DEFINITY® Vial
for (Perflutren Lipid Microsphere) Injectable Suspension and TechneLite®
(Technetium Tc99m Generator), a technetium-based generator that provides
the essential medical isotope used in nuclear medicine procedures. The
Company is headquartered in North Billerica, Massachusetts with offices
in Puerto Rico and Canada. For more information, visit www.lantheus.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190507005767/en/
Source: Lantheus Holdings, Inc.
Investors
Mark Kinarney
978-671-8842
Media
Meara
Murphy
978-671-8508
